Supply Path Optimization for Pharma: What to Remove and Why
A removal rule for pharma supply path optimization that balances transparency, uniqueness, performance, cost, and resilience instead of cutting paths blindly.
The short answer
Supply path optimization means reducing the number of routes through which a buyer purchases the same inventory. The same publisher ad slot is often sold through several exchanges and resellers. Each path adds fees and complexity. Removing redundant paths can lower costs and improve quality. Removing the wrong paths can cut off unique inventory or make delivery fragile.
For a worked example, see the HCP supply path optimization case study.
Why pharma buyers care
Pharma buyers often have strict quality needs, narrow audiences, and endemic publishers that matter disproportionately. A crowded supply chain makes it harder to verify where ads run and how much reaches the publisher. SPO can simplify that. The ANA's programmatic supply chain transparency study documented how much of programmatic spend can be lost to intermediaries and low-quality supply.
A five-test removal rule
Before removing a path, test it against five criteria:
| Test | Question | Remove if... |
|---|---|---|
| Transparency | Is the seller authorized in ads.txt and listed in sellers.json? | Path cannot be verified |
| Uniqueness | Does this path offer inventory or audiences unavailable elsewhere? | Inventory is fully duplicated by a better path |
| Performance | How does quality and outcome performance compare? | Consistently worse on quality metrics |
| Cost | What share of spend reaches the publisher? | Fees are materially higher than alternatives |
| Resilience | Would removing it leave you dependent on a single path? | Removal is safe only if alternatives remain |
A path should usually pass the transparency test to stay at all. The other four are judgments.
Use the standards
ads.txt lets publishers list who is authorized to sell their inventory. sellers.json lets exchanges disclose their sellers. The SupplyChain object records the path an impression took. Together they help trace paths. See how to use them together.
Do not over-cut
Aggressive SPO can backfire:
- Lost unique inventory. Some endemic health publishers sell mainly through one or two exchanges.
- Reduced competition. Fewer paths can mean less bid competition and higher prices over time.
- Fragility. If the one remaining path has an outage, delivery stops.
Keep at least two healthy paths for important publishers where possible.
Measure before and after
Compare quality, cost, and outcomes before and after changes. Watch for shifts in inventory mix and delivery drops. SPO decisions should be revisited as supply changes.
Practical takeaway
For your top publishers, list every path you buy through. Apply the five tests to each. Remove only paths that fail transparency or are clearly dominated on uniqueness, performance, and cost, and keep a backup path for critical inventory.
Sources
- IAB Tech Lab, ads.txt
- IAB Tech Lab, sellers.json
- ANA, Programmatic Media Supply Chain Transparency Study
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.